sharecast

{{ storiesRelated.title }}

Full List Of Stories
18 Sep
ep xbox onenegre i blanc
Tuesday preview: Updates from Ocado, Keywords and French Connection

In the absence of any major UK items in the diary, Tuesday may be given over more to small and mid cap company news, with only Ocado joined by Keywords Studios and French Connection in updating investors.

18 Sep
rotork
Rotork's margin plans deserve higher rating, UBS says as it upgrades

Rotork's plans to improve profit margins can spark a return to a premium rating, said UBS as it upgraded the industrial valves specialist and hiked its share price target.

18 Sep
cbcitylondon
Rentokil loses director in Bell Pott fallout

Rentokil Initial director Chris Geoghegan, who brokered the deal that led to the collapse of public relations firm Bell Pottinger, has left the pest control company with immediate effect.

18 Sep
land securities, bluewater
Land Securities' NAV hit but EPS likely to rise after completing bond tender

Land Securities has completed a £502m bond tender to extend its debt maturity and take advantage of low interest rates, which is expected to knock its net asset value but lift earnings per share.

18 Sep
insurance car accident
Motor insurance prices 'likely to stay flat', Deutsche upgrades Admiral

Motor insurance pricing is set to hold steady as companies benefit from another shift in the sector's dynamics, Deutsche Bank said as it recommendation on Admiral and kept Direct Line and Esure at 'buy'.

18 Sep
ep un avioncombate eurofighter typhoon
BAE Systems takes off after Typhoon deal signed with Qatar

BAE Systems will assemble 24 Typhoon fighter jets to be supplied to Qatar after Defence Secretary Michael Fallon signed a first major arms deal with the Gulf state.

18 Sep
Cathedral City cheese, Dairy Crest
Dairy Crest profits as cheesy feats offset higher cream costs

Dairy Crest Group reported cheese sales volumes and values in the six months to September are ahead of last year, with profit also increased.

18 Sep
Astrazeneca
Syncona's Autolus begins three T-cell cancer trials

One of Syncona's portfolio investments has begun three clinical trials to test the ability of its engineered T-cell therapies in combatting cancer.